2025 - Introduced
Kentucky S.B.128
  • Prohibits Medicaid from denying coverage for a non-opioid in favor of an opioid or establishing more restrictive or extensive utilization controls for non-opioids than the least restrictive or extensive utilization controls for any opioid.
Medicaid Parity
Read Bill
2024 - Passed
Louisiana S.B. 224
  • Directs that the state Medicaid program may not impose more restrictive utilization controls for non-opioid drugs than for opioids.
  • Prohibits Medicaid managed care organizations from denying coverage for a non-opioid prescription prescribed for pain in favor of an opioid.
  • Directs the state to create education, awareness and technical assistance materials on the advantage of non-opioid drugs and provide assistance with grants that promote non-opioid pain drugs.
EducationMedicaid Parity
Read Bill
2025 - Introduced
Maryland H.B. 1013/S.B. 974
  • Prohibits prior authorization requirements, step therapy protocol, or fail-first protocol for a non-opioid that is more restrictive than requirements for an opioid.
Medicaid ParityState Regulated Commercial Parity
Read House BillRead Senate Bill
2025 - Introduced
Massachusetts H.1134/S.863
  • Requires MassHealth (Medicaid) and its contracted plans to cover FDA-approved non-opioid pain medications on parity with opioids by prohibiting more restrictive coverage, prior authorization, or step therapy requirements.
  • Expands Medicaid chronic pain care through integrated services, quality strategies, provider training, and statewide data collection and reporting on chronic pain prevalence and costs.
Medicaid Parity
Read House BillRead Senate Bill
2025 - Introduced
Michigan S.B. 551
  • Requires Michigan Medicaid to cover non-opioid pain medications and add them to the preferred drug list within 90 days.
  • Prohibits prior authorization and expands existing Medicaid protections that exempt certain drugs from prior authorization.
Medicaid Parity
Read Senate Bill
2025 - Introduced
Minnesota S.F. 1947/H.F. 1807
  • Requires that in establishing and maintaining Minnesota's preferred drug list, health insurers must not disadvantage or discourage a non-opioid drug with respect to coverage of an opioid drug.
Medicaid Parity
Read Senate BillRead House Bill
2025 - Introduced
Mississippi H.B.1389
  • Prohibits practices that disadvantage or discourage the use of non-opioid drugs relative to opioids in state Medicaid program.
Medicaid Parity
Read Bill
2026 - Introduced
Missouri S.B. 1024
Limits initial opioid prescriptions for acute pain in Missouri to a seven-day supply, requires practitioners to discuss risks, alternatives, and dosing options with patients, and mandates documentation if a longer supply is medically necessary.
Medicaid ParityState Employee Health Plan Parity
Read Senate Bill
2025 - Introduced
Montana H.B. 774
  • Prohibits Medicaid and health insurers from denying coverage of a non-opioid in favor of an opioid and requires that in establishing a drug formulary, the Montana Department of Public Health and Human Services must ensure a non-opioid is not disadvantaged or discouraged as compared to coverage of an opioid.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Introduced
Nebraska L.B. 252
  •  Requires Medicaid and commercial plans to treat non-opioid medications equally to opioids, prohibits restrictions, higher cost-sharing, and allows prescribers to override coverage restrictions when appropriate.
  • Takes effect immediately upon FDA approval of a non-opioid drug and aims to improve access to non-opioid pain management.
Medicaid Parity
Read Bill
2025 - Introduced
Nevada S.B. 377
  • Requires health insurers and Medicaid cover at least one alternative to an opioid and prohibits insurers from requiring prior authorization or other restrictive requirements for an alternative to an opioid compared to requirements established for an opioid.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2024 - Introduced
New Jersey A4682
  • Prohibits health insurers, Medicaid and School Employees’ Health Benefits from denying coverage of non-opioid prescription drugs in favor of opioid prescription drugs. Further, formularies are prohibited from disincentivizing the use of non-opioids with respect to coverage or cost-sharing.
Medicaid ParityState Regulated Commercial Parity
Read Bill